Spring Day 16 March 2022
The UKMF Spring Day took place on Wednesday 16th March 2022. This was a hybrid meeting at the Cavendish Conference Centre in central London, Chaired by Dr Rachel Hall and Dr Neil Rabin
The theme for this meeting was ‘Relapsed Myeloma and the Impact of Covid-19’. Thank you to all our speakers, particularly the Michael Morley guest lecture, Dr Vincent Rajkumar from the Mayo Clinic in Rochester who presented on ‘ How I treat relapsed myeloma: a global perspective’.
The next educational meeting will take place on Wednesday 9th November 2022 at the Cavendish Conference Centre. Details will follow.
Presentations can be downloaded below.
Documents
- Programme
- Myeloma and COVID: Impacts now and in the future
- How I treat early relapse of myeloma
- CAR-T Update
- EFFICACY OF ISATUXIMAB WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED MYELOMA: RESULTS OF A UK-WIDE REAL-WORLD DATASET
- Multistate models demonstrate that lenalidomide maintenance enhances survival by prolonging time in first remission for patients treated in the UK NCRI Myeloma XI randomised trial
- TRIM33 Loss in Multiple Myeloma Impairs the DNA Damage Response Resulting in Sensitivity to PARP and ATR Inhibitors
- 820: Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment
- Daratumumab, Bortezomib and dexamethasone (DVd) at first relapse for patients with Relapsed/ Refractory Multiple Myeloma (RRMM): a UK Myeloma Research Alliance (UK-MRA) real-world multicentre analysis